COMMUNIQUÉS West-GlobeNewswire

Minutes of the General Meeting of 12 May 2026
12/05/2026
Minutes of the General Meeting of 12 May 2026 Paris, 12 May 2026 – The Annual General Meeting of shareholders of Clariane (CLARI - ISIN: FR0010386334) was held on 12 May 2026 (the « General Meeting »), chaired by Sylvia [...]
Compte-rendu de l’Assemblée Générale du 12 Mai 2026
12/05/2026
Compte rendu de l’Assemblée générale du 12 mai 2026 Paris, le 12 mai 2026 – L’Assemblée générale annuelle des actionnaires de la société Clariane (CLARI - ISIN : FR0010386334) s’est réunie le 12 mai 2026 (l’« Assemblée [...]
High Diet Surpasses 1,700 Customer Reviews as Users Praise Personalized High-Protein Meal Plans
12/05/2026
1,700+ customer reviews point to High Diet's personalized high-protein meal plans and fitness tracking as the features keeping users coming back NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- High Diet has launched a [...]
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
12/05/2026
Data will reflect the functional characterization of EVX-04 Poster presentation on June 13, 2026 COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing [...]
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
12/05/2026
Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings Preclinical data from [...]
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
12/05/2026
Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrier to anthracycline [...]
Cellectis présentera des données cliniques sur lasmé-cel et éti-cel au congrès annuel de l’EHA 2026
12/05/2026
NEW YORK, 12 mai 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des [...]
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
12/05/2026
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell [...]
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
12/05/2026
Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session Company to host investor conference call and webcast during EHA 2026 on Saturday, June [...]
Ajax Therapeutics Announces Oral Presentation of Clinical Results from AJX-101, a Phase I study of AJ1-11095, a First-in-Class Type II JAK2 Inhibitor, at the European Hematology Society (EHA) 2026 Congress
12/05/2026
– Company unveils first proof-of concept clinical data of AJ1-11095 in patients with myelofibrosis who have been previously treated with a type I JAK2 Inhibitor – NEW YORK and CAMBRIDGE, Mass., May 12, 2026 (GLOBE [...]
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
12/05/2026
Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT [...]
BlossomHill Therapeutics to Present Initial Clinical Dose Escalation Data from the Phase 1/1b Trial of BH-30236 in Patients with R/R AML or HR-MDS at EHA2026
12/05/2026
Treatment with BH-30236, a novel CLK inhibitor, was generally well tolerated as monotherapy and in combination with venetoclax Preliminary anti-leukemic activity observed, including patients that were previously treated [...]
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
12/05/2026
sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing transfusion burden [...]
LiveWorld's New APP Research Council Gives Brands Direct Access to Frontline NP and PA Insights to Improve Relevance, Reach, and ROI
12/05/2026
Targets a long-overlooked gap in pharma marketing: the APP audience driving half of prescribing decisions CAMPBELL, Calif. and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), a leader in [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
12/05/2026
Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with [...]
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
12/05/2026
– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerability with revumenib [...]
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
12/05/2026
Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, [...]
Extendicare Files Business Acquisition Report in connection with the CBI Home Health Acquisition
12/05/2026
MARKHAM, Ontario, May 12, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) has filed a Business Acquisition Report on Form 51-102F4 (the “BAR”) on SEDAR+ ( www.sedarplus.ca ) in [...]
Becker’s Names Leap Distributors CEO Allen Mason to 2026 Great Leaders in Healthcare List
12/05/2026
DALLAS, May 12, 2026 (GLOBE NEWSWIRE) -- Becker’s Hospital Review has named Leap Distributors Co-founder and CEO Allen Mason to the 2026 list of Great Leaders in Healthcare. Mason is included in the Companies section, [...]

Pages